GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Elicera Therapeutics AB (OSTO:ELIC) » Definitions » Research & Development

Elicera Therapeutics AB (OSTO:ELIC) Research & Development : kr0.00 Mil (TTM As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Elicera Therapeutics AB Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Elicera Therapeutics AB's Research & Development for the three months ended in Jun. 2024 was kr0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2024 was kr0.00 Mil.

Elicera Therapeutics AB Research & Development Historical Data

The historical data trend for Elicera Therapeutics AB's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Elicera Therapeutics AB Research & Development Chart

Elicera Therapeutics AB Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
- - - - -

Elicera Therapeutics AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Elicera Therapeutics AB Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Elicera Therapeutics AB  (OSTO:ELIC) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Elicera Therapeutics AB Research & Development Related Terms

Thank you for viewing the detailed overview of Elicera Therapeutics AB's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Elicera Therapeutics AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Elicera Therapeutics AB (OSTO:ELIC) » Definitions » Research & Development
Comparable Companies
OSTO:ISOFOL OSTO:SPRINT OSTO:ALZ OSTO:BIOVIC B OSTO:NXTCL XSAT:CESSA OSTO:ACE OSTO:ZICC OSTO:SIMRIS B OSTO:LIPUM OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
Massans gata 10, World Trade Center Goteborg, 7th Floor, Goteborg, SWE, SE-412 51
Website
https://www.elicera.com
Elicera Therapeutics AB is a Sweden-based clinical-stage immuno-oncology company developing cell and gene therapies for immune-based cancer treatments. The company's product portfolio consists of four drug candidates, two in the field of oncolytic viruses (ELC-100 and ELC-201) and two in the field of CAR T-cell treatments (ELC-301 and ELC-401), in addition to a universal CAR T-cell technology platform, iTANK (ELC-001), compatible with any CAR T-cell therapy for a multi-targeted attack on solid tumors.

Elicera Therapeutics AB Headlines

No Headlines